Patents by Inventor Stephen S. YOO
Stephen S. YOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250189530Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to BTN1A1. Methods of making and using these molecules are also provided, including methods of using them in detecting the presence of BTN1A1 in a sample, such as a bodily fluid or tissue of a patient, for diagnostics and treatment of BTN1A1 mediated diseases or conditions.Type: ApplicationFiled: March 15, 2023Publication date: June 12, 2025Inventor: Stephen S. YOO
-
Patent number: 12059474Abstract: Methods for producing and screening for antibodies that specifically bind to glycosylated immune checkpoint proteins (ICPs) relative to non-glycosylated ICPs are provided. Such antibodies recognize specific epitopes of glycosylated ICPs and can prevent or block the binding of a glycosylated ICP with its ligand, such as another ICP, and can inhibit the interactions between the two proteins that can lead to immunosuppression, as exemplified by the human PD-L1/PD-1 interaction. By way of specific example, human PD-L1 and PD-1 polypeptides comprising glycosylated amino acid residues within their extracellular domains are provided for generating anti-glycosylated PD-L1 or anti-glycosylated PD-1 antibodies that specifically bind PD-L1 or PD-1, respectively, and inhibit the PD-L1/PD-1 interaction. The antibodies produced and selected by the methods are especially useful as cancer therapeutics for disrupting, blocking, or neutralizing the ICP system and specific ICP interactions therein.Type: GrantFiled: March 24, 2017Date of Patent: August 13, 2024Assignees: STCUBE & CO., INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Mien-Chie Hung
-
Patent number: 11981736Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: GrantFiled: November 13, 2020Date of Patent: May 14, 2024Assignees: ST CUBE INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Seung-Oe Lim, Chia-Wei Li, Mien-Chie Hung
-
Patent number: 11933786Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: GrantFiled: November 13, 2020Date of Patent: March 19, 2024Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXASInventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
-
Patent number: 11746152Abstract: Anti-cancer treatment and therapeutic methods are provided in which an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 and blocks binding of PD-L1 to PD-1 is administered to a subject in need in combination with an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, blocks binding of PD-L1 to PD-1 and also promotes internalization and degradation of PD-L1. The anti-cancer methods utilize antibodies that recognize specific epitopes on glycosylated PD-L1 protein, as well as antibodies that exhibit the IPD function of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells expressing PD-L1. Methods in which such antibody combinations are especially useful include cancer and tumor treatments and therapies in which the cancer or tumor is a PD-L1 positive cancer or tumor.Type: GrantFiled: July 19, 2017Date of Patent: September 5, 2023Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
-
Patent number: 11660352Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, block binding of PD-L1 to PD-1 and promote internalization and degradation of PD-L1 are provided. Antibodies that recognize specific epitopes on glycosylated PD-L1 protein and that exhibit the dual functions of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for using such antibodies for the treatment of cancer, particularly PD-L1 positive cancer, are also provided.Type: GrantFiled: March 24, 2017Date of Patent: May 30, 2023Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Kyu Lee Han, Andrew H. Park, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
-
Publication number: 20220356248Abstract: Antibodies that selectively bind to glycosylated LAG3 relative to unglycosylated LAG3 are provided. In some aspects, LAG3 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: ApplicationFiled: October 9, 2020Publication date: November 10, 2022Inventor: Stephen S. Yoo
-
Publication number: 20220276252Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: ApplicationFiled: November 13, 2020Publication date: September 1, 2022Applicants: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXASInventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
-
Publication number: 20220155307Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: ApplicationFiled: November 13, 2020Publication date: May 19, 2022Applicants: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXASInventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
-
Publication number: 20210139588Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: ApplicationFiled: November 13, 2020Publication date: May 13, 2021Applicants: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Seung-Oe LIM, Chia-Wei LI, Mien-Chie HUNG
-
Patent number: 10858432Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: GrantFiled: December 1, 2016Date of Patent: December 8, 2020Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Seung-Oe Lim, Chia-Wei Li, Mien-Chie Hung
-
Patent number: 10836827Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 are provided. Antibodies that recognize specific epitopes of glycosylated PD-L1 protein and can block the binding of PD-L1 to PD-1 are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: GrantFiled: March 29, 2016Date of Patent: November 17, 2020Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
-
Publication number: 20190218297Abstract: Anti-cancer treatment and therapeutic methods are provided in which an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 and blocks binding of PD-L1 to PD-1 is administered to a subject in need in combination with an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, blocks binding of PD-L1 to PD-1 and also promotes internalization and degradation of PD-L1. The anti-cancer methods utilize antibodies that recognize specific epitopes on glycosylated PD-L1 protein, as well as antibodies that exhibit the IPD function of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells expressing PD-L1. Methods in which such antibody combinations are especially useful include cancer and tumor treatments and therapies in which the cancer or tumor is a PD-L1 positive cancer or tumor.Type: ApplicationFiled: July 19, 2017Publication date: July 18, 2019Inventors: Stephen S. YOO, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
-
Publication number: 20190105403Abstract: Methods for producing and screening for antibodies that specifically bind to glycosylated immune checkpoint proteins (ICPs) relative to non-glycosylated ICPs are provided. Such antibodies recognize specific epitopes of glycosylated ICPs and can prevent or block the binding of a glycosylated ICP with its ligand, such as another ICP, and can inhibit the interactions between the two proteins that can lead to immunosuppression, as exemplified by the human PD-L1/PD-1 interaction. By way of specific example, human PD-L1 and PD-1 polypeptides comprising glycosylated amino acid residues within their extracellular domains are provided for generating anti-glycosylated PD-L1 or anti-glycosylated PD-1 antibodies that specifically bind PD-L1 or PD-1, respectively, and inhibit the PD-L1/PD-1 interaction. The antibodies produced and selected by the methods are especially useful as cancer therapeutics for disrupting, blocking, or neutralizing the ICP system and specific ICP interactions therein.Type: ApplicationFiled: March 24, 2017Publication date: April 11, 2019Inventors: Stephen S. YOO, Mien-Chie HUNG
-
Publication number: 20190083644Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, block binding of PD-L1 to PD-1 and promote internalization and degradation of PD-L1 are provided. Antibodies that recognize specific epitopes on glycosylated PD-L1 protein and that exhibit the dual functions of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for using such antibodies for the treatment of cancer, particularly PD-L1 positive cancer, are also provided.Type: ApplicationFiled: March 24, 2017Publication date: March 21, 2019Inventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Kyu Lee HAN, Andrew H. PARK, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
-
Publication number: 20190077866Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: ApplicationFiled: December 1, 2016Publication date: March 14, 2019Inventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Seung-Oe LIM, Chia-Wei LI, Mien-Chie HUNG
-
Publication number: 20180118830Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 are provided. Antibodies that recognize specific epitopes of glycosylated PD-L1 protein and can block the binding of PD-L1 to PD-1 are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: ApplicationFiled: March 29, 2016Publication date: May 3, 2018Applicants: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXASInventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM